본문 바로가기
KERD
논문KCI 등재

대한천식알레르기학회 알레르기 면역요법 진료지침

The Korean Academy of Asthma Allergy and Clinical Immunology guidelines for allergen immunotherapy

김선태|박경희|최선희|최정희|김주희|박소영|이용원|박중원|이상민|정은희|이영수|김경훈|지혜미|한만용|양은애|민진영|심정연|안영민|신유섭|강성윤|류광희|하은교|이화영|성명순|고영일|남동호|한두희|대한천식알레르기학회 면역요법/알레르겐연구팀
대한 소아알레르기 호흡기학회 (The Korean Academy Of Pediatric Allergy And Respiratory Disease)|2024.07|Allergy Asthma & Respiratory Disease (알레르기 천식 호흡기질환)|제12권 제3호|pp. 102-124|DOI https://doi.org/10.4168/aard.2024.12.3.102

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

GuidelineAllergensImmunotherapy
주제분류소아과학

초록

Allergen immunotherapy (AIT) is a causative treatment of allergic diseases in which allergen extracts are regularly administered in a gradually escalated doses, leading to immune tolerance and consequent alleviation of allergic diseases. The need for uniform practice guidelines in AIT is continuously growing as the number of potential candidates for AIT increases and new therapeutic approaches are tried. This updated version of the Korean Academy of Asthma Allergy and Clinical Immunology recommendations for AIT, published in 2010, proposes an expert opinion by specialists in allergy, pediatrics, and otorhinolaryngology. This guideline deals with the basic knowledge of AIT, including mechanisms, clinical efficacy, allergen standardization, important allergens in Korea, and special consideration in pediatrics. The article also covers the methodological aspects of AIT, including patient selection, allergen selection, schedule and doses, follow-up care, efficacy measurements, and management of adverse reactions. Although this guideline suggests the optimal dosing schedule, an individualized approach and modifications are recommended considering the situation for each patient and clinic.

Abstract

Allergen immunotherapy (AIT) is a causative treatment of allergic diseases in which allergen extracts are regularly administered in a gradually escalated doses, leading to immune tolerance and consequent alleviation of allergic diseases. The need for uniform practice guidelines in AIT is continuously growing as the number of potential candidates for AIT increases and new therapeutic approaches are tried. This updated version of the Korean Academy of Asthma Allergy and Clinical Immunology recommendations for AIT, published in 2010, proposes an expert opinion by specialists in allergy, pediatrics, and otorhinolaryngology. This guideline deals with the basic knowledge of AIT, including mechanisms, clinical efficacy, allergen standardization, important allergens in Korea, and special consideration in pediatrics. The article also covers the methodological aspects of AIT, including patient selection, allergen selection, schedule and doses, follow-up care, efficacy measurements, and management of adverse reactions. Although this guideline suggests the optimal dosing schedule, an individualized approach and modifications are recommended considering the situation for each patient and clinic.

참고문헌 (184)

  1. Jutel M, "International consensus on allergy immunotherapy", J Allergy Clin Immunol, 136, pp.556~568 (2015)
  2. Noon L, "Prophylactic inoculation against hay fever", Lancet, 177, pp.1572~1573 (1911)
  3. Freeman J, "Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Historical document", Ann Allergy, 18, pp.427~434 (1960)
  4. Hur GY, "Allergy immunotherapy", Korean J Asthma Allergy Clin Immunol, 30, pp.153~183 (2010)
  5. Balshem H, "GRADE guidelines: 3. Rating the quality of evidence", J Clin Epidemiol, 64, pp.401~406 (2011)
  6. Shamji MH, "Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma", J Allergy Clin Immunol, 149, pp.791~801 (2022)
  7. Gardner LM, "Induction of T 'regulatory' cells by standardized house dust mite immunotherapy : an increase in CD4+ CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers", Clin Exp Allergy, 34, pp.1209~1219 (2004)
  8. Varona R, "Persistent regulatory T-cell response 2 years after 3 years of grass tablet SLIT : links to reduced eosinophil counts, sIgE levels, and clinical benefit", Allergy, 74, pp.349~360 (2019)
  9. Pavón-Romero GF, "Allergen immunotherapy : current and future trends", Cells, 11, pp.212~ (2022)
  10. Akdis CA, "Mechanisms of allergen-specific immunotherapy", J Allergy Clin Immunol, 127, pp.18~27 (2011)
  11. Zimmer A, "A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy", J Allergy Clin Immunol, 129, pp.1020~1030 (2012)
  12. Shamji MH, "Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers", J Allergy Clin Immunol, 140, pp.1485~1498 (2017)
  13. Schandené L, "B7", CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10, 1994, pp.152, 4368~4374
  14. van de Veen W, "Role of regulatory B cells in immune tolerance to allergens and beyond", J Allergy Clin Immunol, 138, pp.654~665 (2016)
  15. Golden DB, "Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy", J Allergy Clin Immunol, 69, pp.489~493 (1982)
  16. Müller U, "Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom", Allergy, 44, pp.412~418 (1989)
  17. Wachholz PA, "Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy", J Allergy Clin Immunol, 112, pp.915~922 (2003)
  18. Mitthamsiri W, "Decreased CRTH2 expression and response to allergen re-stimulation on innate lymphoid cells in patients with allergen-specific immunotherapy", Allergy Asthma Immunol Res, 10, pp.662~674 (2018)
  19. Eljaszewicz A, "Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy", J Allergy Clin Immunol, 147, pp.1865~1877 (2021)
  20. Bohle B, "Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation", J Allergy Clin Immunol, 120, pp.707~713 (2007)
  21. Heeringa JJ, "Induction of IgG(2)and IgG(4)B-cell memory following sublingual immunotherapy for ryegrass pollen allergy", Allergy, 75, pp.1121~1132 (2020)
  22. Couroux P, "A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG(4)to allergens from all trees in the birch homologous group", Allergy, 74, pp.361~369 (2019)
  23. James C, "Allergen immunotherapy : an updated review of safety", Curr Opin Allergy Clin Immunol, 17, pp.55~59 (2017)
  24. Sturm GJ, "EAACI guidelines on allergen immunotherapy : Hymenoptera venom allergy", Allergy, 73, pp.744~764 (2018)
  25. Golden DB, "Stinging insect hypersensitivity : a practice parameter update 2016", Ann Allergy Asthma Immunol, 118, pp.28~54 (2017)
  26. Canonica GW, "Sublingual immunotherapy : World Allergy Organization position paper 2013 update", World Allergy Organ J, 7, pp.6~ (2014)
  27. Malling HJ, "Subcutaneous immunotherapy for allergic rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases", Clin Allergy Immunol, 21, pp.343~358 (2008)
  28. Brozek JL, "Allergic Rhinitis and its Impact on Asthma(ARIA)guidelines : 2010 revision", J Allergy Clin Immunol, 126, pp.466~476 (2010)
  29. Ariano R, "Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial", Allergy, 54, pp.313~319 (1999)
  30. Malling HJ, "Diagnosis and immunotherapy of mould allergy. VIII. Qualitative and quantitative estimation of IgE in Cladosporium immunotherapy", Allergy, 43, pp.228~238 (1988)
  31. Alvarez-Cuesta E, "Monoclonal antibody-standardized cat extract immunotherapy : risk-benefit effects from a double-blind placebo study", J Allergy Clin Immunol, 93, pp.556~566 (1994)
  32. Aas K, "Hyposensitization in house dust allergy asthma. A double-blind controlled study with evaluation of the effect on bronchial sensitivity to house dust", Acta Paediatr Scand, 60, pp.264~268 (1971)
  33. Roberts G, "EAACI Guidelines on Allergen Immunotherapy : allergic rhinoconjunctivitis", Allergy, 73, pp.765~798 (2018)
  34. Abramson MJ, "Injection allergen immunotherapy for asthma", Cochrane Database Syst Rev, (8), pp.CD001186~ (2010)
  35. Erekosima N, "Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma : a systematic review", Laryngoscope, 124, pp.616~627 (2014)
  36. Lin SY, "Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma : a systematic review", JAMA, 309, pp.1278~1288 (2013)
  37. Mosbech H, "Standardized quality(SQ)house dust mite sublingual immunotherapy tablet(ALK)reduces inhaled corticosteroid use while maintaining asthma control : a randomized, double-blind, placebo-controlled trial", J Allergy Clin Immunol, 134, pp.568~575 (2014)
  38. de Blay F, "SQ HDM SLIT-tablet(ALK)in treatment of asthma--post hoc results from a randomised trial", Respir Med, 108, pp.1430~1437 (2014)
  39. Passalacqua G, "The safety of allergen specific sublingual immunotherapy", Curr Drug Saf, 2, pp.117~123 (2007)
  40. Penagos M, "Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age", Chest, 133, pp.599~609 (2008)
  41. Khinchi MS, "Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy : a randomized, placebo-controlled, double-blind, double-dummy study", Allergy, 59, pp.45~53 (2004)
  42. Hansen KS, "Food allergy to apple and specific immunotherapy with birch pollen", Mol Nutr Food Res, 48, pp.441~448 (2004)
  43. Kinaciyan T, "Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1", J Allergy Clin Immunol, 119, pp.937~943 (2007)
  44. Sampson HA, "Food allergy : a practice parameter update-2014", J Allergy Clin Immunol, 134, pp.1016~1025 (2014)
  45. Muraro A, "EAACI food allergy and anaphylaxis guidelines : diagnosis and management of food allergy", Allergy, 69, pp.1008~1025 (2014)
  46. Skypala IJ, "BSACI guideline for the diagnosis and management of pollen food syndrome in the UK", Clin Exp Allergy, 52, pp.1018~1034 (2022)
  47. Biedermann T, "The SQ tree SLIT-tablet is highly effective and well tolerated : results from a randomized, double-blind, placebo-controlled phase III trial", J Allergy Clin Immunol, 143, pp.1058~1066 (2019)
  48. Till SJ, "Potential treatment effect of the SQ tree SLIT-tablet on pollen food syndrome caused by apple", Allergy, 75, pp.2059~2061 (2020)
  49. Werfel T, "Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites : a multi-centre, randomized, dose-response study", Allergy, 61, pp.202~205 (2006)
  50. Nahm DH, "Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex", Int Arch Allergy Immunol, 146, pp.235~240 (2008)
  51. Yepes-Nunez JJ, "Allergen immunotherapy for atopic dermatitis : systematic review and meta-analysis of benefits and harms", J Allergy Clin Immunol, 151, pp.147~158 (2023)
  52. Bae JM, "Efficacy of allergen-specific immunotherapy for atopic dermatitis : a systematic review and meta-analysis of randomized controlled trials", J Allergy Clin Immunol, 132, pp.110~117 (2013)
  53. Nurmatov U, "Allergen immunotherapy for IgE-mediated food allergy : a systematic review and meta-analysis", Allergy, 72, pp.1133~1147 (2017)
  54. Pajno GB, "EAACI Guidelines on allergen immunotherapy : IgE-mediated food allergy", Allergy, 73, pp.799~815 (2018)
  55. Bousquet J, "Allergic Rhinitis and its Impact on Asthma(ARIA)2008 update(in collaboration with the World Health Organization, GA(2)LEN and AllerGen)", Allergy, 63(Suppl 86), pp.8~160 (2008)
  56. Dhami S, "Allergen immunotherapy for allergic rhinoconjunctivitis : a systematic review and meta-analysis", Allergy, 72, pp.1597~1631 (2017)
  57. Bousquet J, "Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology", Ann Allergy Asthma Immunol, 81, pp.401~405 (1998)
  58. Moote W, "Allergen-specific immunotherapy", Allergy Asthma Clin Immunol, 14(Suppl 2), pp.53~ (2018)
  59. Halken S, "EAACI guidelines on allergen immunotherapy : prevention of allergy", Pediatr Allergy Immunol, 28, pp.728~745 (2017)
  60. Bachert C, "Allergen immunotherapy on the way to product-based evaluation-a WAO statement", World Allergy Organ J, 8, pp.29~ (2015)
  61. Pfaar O, "Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases : S2k Guideline of the German Society for Allergology and Clinical Immunology(DGAKI), the Society for Pediatric Allergy and Environmental Medicine(GPA), the Medical Association of German Allergologists(AeDA), the Austrian Society for Allergy and Immunology(OGAI), the Swiss Society for Allergy and Immunology(SGAI), the German Society of Dermatology(DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery(DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine(DGKJ), the Society for Pediatric Pneumology(GPP), the German Respiratory Society(DGP), the German Association of ENT Surgeons(BV-HNO), the Professional Federation of Paediatricians and Youth Doctors(BVKJ), the Federal Association of Pulmonologists(BDP)and the German Dermatologists Association(BVDD)", Allergo J Int, 23, pp.282~319 (2014)
  62. Reisman RE, "A double-blind study of the effectiveness of a high-efficiency particulate air(HEPA)filter in the treatment of patients with perennial allergic rhinitis and asthma", J Allergy Clin Immunol, 85, pp.1050~1057 (1990)
  63. Terreehorst I, "Evaluation of impermeable covers for bedding in patients with allergic rhinitis", N Engl J Med, 349, pp.237~246 (2003)
  64. Jeon YH, "Effects of vacuuming mattresses on allergic rhinitis symptoms in children", Allergy Asthma Immunol Res, 11, pp.655~663 (2019)
  65. Park KH, "Effects of air purifiers on patients with allergic rhinitis : a multicenter, randomized, double-blind, and placebo-controlled study", Yonsei Med J, 61, pp.689~697 (2020)
  66. Stillerman A, "Efficacy of a novel air filtration pillow for avoidance of perennial allergens in symptomatic adults", Ann Allergy Asthma Immunol, 104, pp.440~449 (2010)
  67. Wood RA, "A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy", Am J Respir Crit Care Med, 158, pp.115~120 (1998)
  68. Bjornsdottir US, "The effect of reducing levels of cat allergen(Fel d 1)on clinical symptoms in patients with cat allergy", Ann Allergy Asthma Immunol, 91, pp.189~194 (2003)
  69. Gherasim A, "Efficacy of air cleaners in asthmatics allergic to cat in ALYATEC((R))environmental exposure chamber", Clin Exp Allergy, 50, pp.160~169 (2020)
  70. Muller UR, "Hymenoptera venom allergy : analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m1 and Ves v5", Allergy, 64, pp.543~548 (2009)
  71. Canonica GW, "Sub-lingual immunotherapy : World Allergy Organization Position Paper 2009", Allergy, 64(Suppl 91), pp.1~59 (2009)
  72. Wilson DR, "Sublingual immunotherapy for allergic rhinitis : systematic review and meta-analysis", Allergy, 60, pp.4~12 (2005)
  73. Cox L, "Allergen immunotherapy : a practice parameter third update", J Allergy Clin Immunol, 127(1 Suppl), pp.S1~S55 (2011)
  74. Oykhman P, "Allergen immunotherapy in pregnancy", Allergy Asthma Clin Immunol, 11, pp.31~ (2015)
  75. Henmar H, "Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy", Clin Exp Immunol, 153, pp.316~323 (2008)
  76. Park HS, "Allergen standardization of Dermatophagoides farinae (D. farinae) extracts", Korean J Allergy, 16, pp.19~25 (1996)
  77. Frew AJ, "Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis", J Allergy Clin Immunol, 117, pp.319~325 (2006)
  78. Ewan PW, "Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite", Clin Allergy, 18, pp.501~508 (1988)
  79. Haugaard L, "A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite : clinical efficacy and side effects", J Allergy Clin Immunol, 91, pp.709~722 (1993)
  80. Olsen OT, "A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults", Allergy, 52, pp.853~859 (1997)
  81. Van Metre TE, "A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever", J Allergy Clin Immunol, 66, pp.500~513 (1980)
  82. Creticos PS, "Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy", J Clin Invest, 76, pp.2247~2253 (1985)
  83. Creticos PS, "Responses to ragweed-pollen nasal challenge before and after immunotherapy", J Allergy Clin Immunol, 84, pp.197~205 (1989)
  84. Furin MJ, "Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity", J Allergy Clin Immunol, 88, pp.27~32 (1991)
  85. Varney VA, "Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs", BMJ, 302, pp.265~269 (1991)
  86. Dolz I, "A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy", Allergy, 51, pp.489~500 (1996)
  87. Walker SM, "Grass pollen immunotherapy for seasonal rhinitis and asthma : a randomized, controlled trial", J Allergy Clin Immunol, 107, pp.87~93 (2001)
  88. Bodtger U, "The safety and efficacy of subcutaneous birch pollen immunotherapy-a one-year, randomised, double-blind, placebo-controlled study", Allergy, 57, pp.297~305 (2002)
  89. Hedlin G, "Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment", J Allergy Clin Immunol, 87, pp.955~964 (1991)
  90. Varney VA, "Clinical efficacy of specific immunotherapy to cat dander : a double-blind placebo-controlled trial", Clin Exp Allergy, 27, pp.860~867 (1997)
  91. Ewbank PA, "A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract", J Allergy Clin Immunol, 111, pp.155~161 (2003)
  92. Nanda A, "Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract", J Allergy Clin Immunol, 114, pp.1339~1344 (2004)
  93. Lent AM, "Immunologic response to administration of standardized dog allergen extract at differing doses", J Allergy Clin Immunol, 118, pp.1249~1256 (2006)
  94. Horst M, "Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract", J Allergy Clin Immunol, 85, pp.460~472 (1990)
  95. Kuna P, "Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children", J Allergy Clin Immunol, 127, pp.502~508 (2011)
  96. Abramson MJ, "Allergen immunotherapy for asthma", Cochrane Database Syst Rev, (2), pp.CD001186~ (2000)
  97. Agache I, "EAACI Guidelines on Allergen Immunotherapy : house dust mite-driven allergic asthma", Allergy, 74, pp.855~873 (2019)
  98. Aalberse RC, "Molecular allergology user's guide 2.0", The European Academy of Allergy and Clinical Immunology (EAACI), ~ (2022)
  99. Arshad SH, "Sensitization to common allergens and its association with allergic disorders at age 4 years : a whole population birth cohort study", Pediatrics, 108, pp.E33~ (2001)
  100. Bousquet PJ, "Assessment of allergen sensitization in a general population-based survey(European Community Respiratory Health Survey I)", Ann Epidemiol, 20, pp.797~803 (2010)
  101. Calderon MA, "Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients : looking at the published evidence", J Allergy Clin Immunol, 129, pp.929~934 (2012)
  102. Ciprandi G, "Characteristics of patients with allergic polysensitization : the POLISMAIL study", Eur Ann Allergy Clin Immunol, 40, pp.77~83 (2008)
  103. Demoly P, "Management of the polyallergic patient with allergy immunotherapy : a practice-based approach", Allergy Asthma Clin Immunol, 12, pp.2~ (2016)
  104. Kim YJ, "Trends of Sensitization to Inhalant Allergens in Korean Children Over the Last 10 Years", Yonsei Med J, 61, pp.797~804 (2020)
  105. Kim HY, "Determinants of sensitization to allergen in infants and young children", Korean J Pediatr, 57, pp.205~210 (2014)
  106. Hur GY, "A survey of the prescription patterns of allergen immunotherapy in Korea", Allergy Asthma Immunol Res, 5, pp.277~282 (2013)
  107. Burbach GJ, "GA(2)LEN skin test study II : clinical relevance of inhalant allergen sensitizations in Europe", Allergy, 64, pp.1507~1515 (2009)
  108. Mahler V, "Understanding differences in allergen immunotherapy products and practices in North America and Europe", J Allergy Clin Immunol, 143, pp.813~828 (2019)
  109. Kim TB, "Sensitization rates for inhalant allergens in Korea : a multicenter study", Korean J Asthma Allergy Clin Immnol, 23, pp.283~293 (2007)
  110. Adkinson NF Jr, "A controlled trial of immunotherapy for asthma in allergic children", N Engl J Med, 336, pp.324~331 (1997)
  111. Yang MS, "Dog and cat allergies and allergen avoidance measures in Korean adult pet owners who participated in a pet exhibition", Allergy Asthma Immunol Res, 10, pp.155~164 (2018)
  112. Kang SY, "The role of allergen-specific IgE in predicting allergic symptoms on dog and cat exposure among Korean pet exhibition participants", World Allergy Organ J, 13, pp.100488~ (2020)
  113. Twaroch TE, "Mold allergens in respiratory allergy : from structure to therapy", Allergy Asthma Immunol Res, 7, pp.205~220 (2015)
  114. Kordash TR, "Effect of mixing allergenic extracts containing Helminthosporium, D. farinae, and cockroach with perennial ryegrass", Ann Allergy, 71, pp.240~246 (1993)
  115. Lee YW, "Cross-allergenicity of pollens from the Compositae family : Artemisia vulgaris, Dendranthema grandiflorum, and Taraxacum officinale", Ann Allergy Asthma Immunol, 99, pp.526~533 (2007)
  116. Leavengood DC, "Cross allergenicity among grasses determined by tissue threshold changes", J Allergy Clin Immunol, 76, pp.789~794 (1985)
  117. Nelson HS, "Studies of allergen extract stability : the effects of dilution and mixing", J Allergy Clin Immunol, 98, pp.382~388 (1996)
  118. Grier TJ, "Stability of standardized grass, dust mite, cat, and short ragweed allergens after mixing with mold or cockroach extracts", Ann Allergy Asthma Immunol, 99, pp.151~160 (2007)
  119. Anderson MC, "Antigenic and allergenic changes during storage of a pollen extract", J Allergy Clin Immunol, 69, pp.3~10 (1982)
  120. Sridhara S, "A study on antigenic and allergenic changes during storage in three different biological extracts", Asian Pac J Allergy Immunol, 10, pp.33~38 (1992)
  121. Alvarez-Cuesta E, "Standards for practical allergen-specific immunotherapy", Allergy, 61(Suppl 82), pp.1~20 (2006)
  122. Allergen immunotherapy, "a practice parameter second update", J Allergy Clin Immunol, 120, pp.S25~S85 (2007)
  123. Tabar AI, "Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy", J Investig Allergol Clin Immunol, 9, pp.155~164 (1999)
  124. Casanovas M, "Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts", Int Arch Allergy Immunol, 139, pp.153~158 (2006)
  125. Harvey SM, "Safety of rush immunotherapy to multiple aeroallergens in an adult population", Ann Allergy Asthma Immunol, 92, pp.414~419 (2004)
  126. Kim ME, "Safety of accelerated schedules of subcutaneous allergen immunotherapy with house dust mite extract in patients with atopic dermatitis", J Korean Med Sci, 26, pp.1159~1164 (2011)
  127. Lee SH, "Safety of ultra-rush schedule of subcutaneous allergen immunotherapy with house dust mite extract conducted in an outpatient clinic in patients with atopic dermatitis and allergic rhinitis", Allergy Asthma Immunol Res, 11, pp.846~855 (2019)
  128. Nielsen L, "Antihistamine premedication in specific cluster immunotherapy : a double-blind, placebo-controlled study", J Allergy Clin Immunol, 97, pp.1207~1213 (1996)
  129. Wang L, "Antihistamine premedication improves safety and efficacy of allergen immunotherapy", Ann Allergy Asthma Immunol, 127, pp.363~371 (2021)
  130. Brockow K, "Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy : a prospective, randomized, placebo-controlled trial", J Allergy Clin Immunol, 100, pp.458~463 (1997)
  131. Tabar AI, "Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus", J Allergy Clin Immunol, 116, pp.109~118 (2005)
  132. Temiño VM, "Safety of multiple aeroallergen rush immunotherapy using a modified schedule", Allergy Asthma Proc, 34, pp.255~260 (2013)
  133. Rieker-Schwienbacher J, "Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients", Clin Transl Allergy, 3, pp.16~ (2013)
  134. Kim JT, "Comparison of allergenic properties among commercially available house dust mite allergen extracts in Korea", Yonsei Med J, 62, pp.86~90 (2021)
  135. Amin HS, "Evaluation of near-fatal reactions to allergen immunotherapy injections", J Allergy Clin Immunol, 117, pp.169~175 (2006)
  136. Tankersley MS, "Local reactions during allergen immunotherapy do not require dose adjustment", J Allergy Clin Immunol, 106, pp.840~843 (2000)
  137. Roy SR, "Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy", Ann Allergy Asthma Immunol, 99, pp.82~86 (2007)
  138. Malling HJ, "Minimising the risks of allergen-specific injection immunotherapy", Drug Saf, 23, pp.323~332 (2000)
  139. Lockey RF, "Systemic reactions and fatalities associated with allergen immunotherapy", Ann Allergy Asthma Immunol, 87, pp.47~55 (2001)
  140. Bernstein DI, "Twelve-year survey of fatal reactions to allergen injections and skin testing : 1990-2001", J Allergy Clin Immunol, 113, pp.1129~1136 (2004)
  141. Lang DM, "Elevated risk of anaphylactoid reaction from radiographic contrast media is associated with both beta-blocker exposure and cardiovascular disorders", Arch Intern Med, 153, pp.2033~2040 (1993)
  142. Muller UR, "Use of beta-blockers during immunotherapy for Hymenoptera venom allergy", J Allergy Clin Immunol, 115, pp.606~610 (2005)
  143. Joint Task Force on Practice Parameters, "Allergen immunotherapy : a practice parameter second update", J Allergy Clin Immunol, 120(3 Suppl), pp.S25~S85 (2007)
  144. Cox L, "Speaking the same language : the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System", J Allergy Clin Immunol, 125, pp.569~574 (2010)
  145. Pumphrey RS, "Lessons for management of anaphylaxis from a study of fatal reactions", Clin Exp Allergy, 30, pp.1144~1150 (2000)
  146. Joint Task Force on Practice Parameters, "The diagnosis and management of anaphylaxis : an updated practice parameter", J Allergy Clin Immunol, 115(3 Suppl 2), pp.S483~S523 (2005)
  147. Bousquet J, "Next-generation Allergic Rhinitis and Its Impact on Asthma(ARIA)guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation(GRADE)and real-world evidence", J Allergy Clin Immunol, 145, pp.70~80 (2020)
  148. Bousquet PJ, "Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis", J Allergy Clin Immunol, 123, pp.1349~1354 (2009)
  149. Corrigan CJ, "Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid", Allergy, 60, pp.801~807 (2005)
  150. Moller C, "Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis(the PAT-study)", J Allergy Clin Immunol, 109, pp.251~256 (2002)
  151. Pfaar O, "Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis : an EAACI Position Paper", Allergy, 69, pp.854~867 (2014)
  152. Shamji MH, "Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma : an EAACI Position Paper", Allergy, 72, pp.1156~1173 (2017)
  153. Di Lorenzo G, "Evaluation of serum s-IgE", total IgE ratio in predicting clinical response to allergen-specific immunotherapy, 2009, pp.123, 1103~1110
  154. Li Q, "Predictive factors for clinical response to allergy immunotherapy in children with asthma and rhinitis", Int Arch Allergy Immunol, 164, pp.210~217 (2014)
  155. Reisinger J, "Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity", J Allergy Clin Immunol, 116, pp.347~354 (2005)
  156. Lima MT, "Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis : a randomized controlled trial", Clin Exp Allergy, 32, pp.507~514 (2002)
  157. Bousquet J, "Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment", J Allergy Clin Immunol, 76, pp.734~744 (1985)
  158. Francis JN, "Grass pollen immunotherapy : IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity", J Allergy Clin Immunol, 121, pp.1120~1125 (2008)
  159. Des Roches A, "Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation", Allergy, 51, pp.430~433 (1996)
  160. Bousquet J, "Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid", J Allergy Clin Immunol, 85, pp.490~497 (1990)
  161. Kim JK, "Development of airway allergic diseases and immunotherapy in children", Korean J Otorhinolaryngol-Head Neck Surg, 62, pp.261~269 (2019)
  162. Rosenstreich DL, "The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma", N Engl J Med, 336, pp.1356~1363 (1997)
  163. Alvaro-Lozano M, "EAACI Allergen Immunotherapy User's Guide", Pediatr Allergy Immunol, 25(Suppl 25), pp.1~101 (2020)
  164. Pfaar O, "One hundred and ten years of Allergen Immunotherapy : a journey from empiric observation to evidence", Allergy, 77, pp.454~468 (2022)
  165. Yu N, "Sublingual immunotherapy in mite-sensitized patients with atopic dermatitis : a randomized controlled study", Postepy Dermatol Alergol, 38, pp.69~74 (2021)
  166. Kristiansen M, "Allergen immunotherapy for the prevention of allergy : a systematic review and meta-analysis", Pediatr Allergy Immunol, 28, pp.18~29 (2017)
  167. Davila I, "Consensus document on dog and cat allergy", Allergy, 73, pp.1206~1222 (2018)
  168. Larenas-Linnemann D, "Clinical evaluation and management of patients with suspected fungus sensitivity", J Allergy Clin Immunol Pract, 4, pp.405~414 (2016)
  169. Portnoy J, "Environmental assessment and exposure reduction of cockroaches : a practice parameter", J Allergy Clin Immunol, 132, pp.802~808 (2013)
  170. Wahn U, "Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis", J Allergy Clin Immunol, 123, pp.160~166 (2009)
  171. Bufe A, "Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy", J Allergy Clin Immunol, 123, pp.167~173 (2009)
  172. Rienzo VD, "Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years", Clin Exp Allergy, 35, pp.560~564 (2005)
  173. Fiocchi A, "Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years", Ann Allergy Asthma Immunol, 95, pp.254~258 (2005)
  174. Agostinis F, "Safety of sublingual immunotherapy with a monomeric allergoid in very young children", Allergy, 60, pp.133~ (2005)
  175. Shao J, "Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis", Am J Rhinol Allergy, 28, pp.131~139 (2014)
  176. Pajno GB, "Adherence to sublingual immunotherapy in preschool children", Pediatr Allergy Immunol, 23, pp.688~689 (2012)
  177. Karakoc-Aydiner E, "Long-Term effect of sublingual and subcutaneous immunotherapy in dust mite-allergic children with asthma", rhinitis : a 3-year prospective randomized controlled trial, 2015, pp.25, 334~342
  178. Eifan AO, "Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic", rhinitis children sensitized to house dust mite : an open randomized controlled trial, 2010, pp.40, 922~932
  179. Yukselen A, "Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma : a randomized, placebo-controlled, double-blind, double-dummy study", Int Arch Allergy Immunol, 157, pp.288~298 (2012)
  180. Keles S, "A novel approach in allergen-specific immunotherapy : combination of sublingual and subcutaneous routes", J Allergy Clin Immunol, 128, pp.808~815 (2011)
  181. Dhami S, "Allergen immunotherapy for allergic asthma : a systematic review and meta-analysis", Allergy, 72, pp.1825~1848 (2017)
  182. Pajno GB, "Clinical practice recommendations for allergen-specific immunotherapy in children : the Italian consensus report", Ital J Pediatr, 43, pp.13~ (2017)
  183. Calderon MA, "Perspectives on allergen-specific immunotherapy in childhood : an EAACI position statement", Pediatr Allergy Immunol, 23, pp.300~306 (2012)
  184. Arasi S, "Efficacy and safety of sublingual immunotherapy in children", Expert Rev Clin Immunol, 12, pp.49~56 (2016)

관련 논문AI추천

대한천식알레르기학회 설하면역요법 진료지침강성윤, 고영일, 김경훈, 김선태, 김주희, 남동호, 류광희, 민진영, 박경희, 박소영, 박중원, 성명순, 신유섭, 심정연, 안영민, 양은애, 이상민, 이영수, 이용원, 이화영, 정은희, 지혜미, 최선희, 최정희, 하은교, 한두희, 한만용, 대한천식알레르기학회 면역요법/알레르겐연구팀대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2024 · 제12권 제3호알레르기성 호흡기 질환에서의 항원특이면역요법강성윤, 양민석, 이상민, 이상표대한내과학회 · 대한내과학회지2020 · 제95권 제6호집먼지진드기에 감작된 소아 천식 및 알레르기비염에서 피하 및 설하 면역요법 효과 비교이은, 김민주, 양송이, 유진호, 홍수종대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2015 · 제3권 제3호대한천식알레르기학회 알레르기비염 진료지침: 파트 2. 비약물치료의 업데이트강성윤, 김도현, 김동규, 김미애, 김민지, 김봉성, 김수환, 김현정, 김효빈, 류광희, 박도양, 박상철, 양송이, 양현종, 이상민, 이용주, 이일환, 이현종, 전영준, 정수지, 최길순, 최정희대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2023 · 제11권 제3호알레르기비염의 치료에 있어서의 설하면역요법의 역할김성완, 정수영대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2014 · 제2권 제2호소아에서 시행한 초급속 면역 치료의 안전성권재우, 김자경, 박진성, 이근무, 조상원대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2017 · 제5권 제6호

이 간행물의 다른 논문 (7건)

메타콜린 기관지유발검사의 임상적 고찰김소리pp. 99-101대한천식알레르기학회 설하면역요법 진료지침신유섭, 김선태, 박경희, 최선희, 최정희, 김주희, 이화영, 박소영, 이용원, 박중원, 이상민, 정은희, 이영수, 김경훈, 지혜미, 한만용, 양은애, 민진영, 심정연, 안영민, 강성윤, 하은교, 성명순, 고영일, 남동호, 한두희, 대한천식알레르기학회 면역요법/알레르겐연구팀, 류광희pp. 125-133오존이 천식 환자의 혈액 내 접합 단백 클라우딘4와 클라우딘5에 미치는 영향안민혁, 이푸른하늘, 황다연, 장안수, 김병곤pp. 134-139메타콜린 기관지유발검사의 세 프로토콜 비교손지우, 김세훈, 이상민, 김태범, 이상표, 강성윤pp. 140-146소아 갈치알레르기: 대구 특이 IgE 검사 활용성 및 대구와의 교차반응박경희, 이수영, 박중원, 정경욱, 염상화, 프레브산 간툴가pp. 147-154
원문 보기